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Oculopharyngeal muscular dystrophy (OPMD) is a late-onset muscular dystrophy caused by a polyalanine
expansion mutation in the coding region of the poly-(A) binding protein nuclear 1 (PABPN1) gene. In unaf-
fected individuals, (GCG)6 encodes the ﬁrst 6 alanines in a homopolymeric stretch of 10 alanines. In most
patients, this (GCG)6 repeat is expanded to (GCG)8–13, leading to a stretch of 12–17 alanines in mutant
PABPN1, which is thought to confer a toxic gain of function. Thus, OPMD has been modelled by expressing
mutant PABPN1 transgenes in the presence of endogenous copies of the gene in cells and mice. In these
models, increased apoptosis is seen, but it is unclear whether this process mediates OPMD. The role of apop-
tosis in the pathogenesis of different muscular dystrophies is unclear. Blocking apoptosis ameliorates
muscle disease in some mouse models of muscular dystrophy such as laminin a-2-deﬁcient mice, but not
in others such as dystrophin-deﬁcient (mdx) mice. Here we demonstrate that apoptosis is not only involved
in the pathology of OPMD but also is a major contributor to the muscle weakness and dysfunction in this dis-
ease. Genetically blocking apoptosis by over-expressing BCL2 ameliorates muscle weakness in our mouse
model of OPMD (A17 mice). The effect of BCL2 co-expression on muscle weakness is transient, since muscle
weakness is apparent in mice expressing both A17 and BCL2 transgenes at late time points. Thus, while
apoptosis is a major pathway that causes muscle weakness in OPMD, other cell death pathways may also
contribute to the disease when apoptosis is inhibited.
INTRODUCTION
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset,
progressive muscular dystrophy that typically presents with
the symptoms of ptosis and dysphagia (1,2) and can proceed
to affect all voluntary muscles, leading to proximal muscle
weakness (3,4) and a severely impaired quality of life. OPMD
is generally inherited as an autosomal dominant trait, but reces-
sive forms do rarely occur (5). The mutation that causes OPMD
was identiﬁed in 1998 and is an abnormal expansion of a
(GCG)n trinucleotide repeat in the coding region of the
poly-(A)bindingproteinnuclear 1(PABPN1)gene(6).Inunaf-
fected individuals, (GCG)6 codes for the ﬁrst 6 alanines in a
homopolymeric stretch of 10 alanines. In most patients, this
(GCG)6 repeat is expanded to (GCG)8–13, leading to a stretch
of 12–17 alanines in mutant PABPN1. PABPN1 with an
expanded polyalanine tract forms aggregates consisting of
tubular ﬁlaments within the nuclei of skeletal muscle ﬁbres
(6–8).OPMDisthoughttobecausedbyatoxicgainoffunction
of the polyalanine expansion mutation. Thus, the cell (9–11),
mouse (12,13) and Drosophila (14) models of OPMD have
been generated by expressing mutant PABPN1 transgenes in
the presence of endogenous copies of the gene.
WehavedevelopedamousemodelofOPMDbyexpressinga
mutantPABPN1transgene(witha17alaninerepeat,thelongest
OPMD-causing expansion; A17 mice) under control of the
human skeletal actin promoter to drive muscle-speciﬁc
expression (12). A17 mice appear normal at birth, but develop
a progressive muscle weakness that is accompanied by the
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nuclei of skeletal myocytes. This phenotype is not seen in
mice expressing a wild-type PABPN1 transgene (with 10
alanine repeat; A10) at similar levels (12). A17 mice have elev-
ated levels of apoptosis, as shown by increased TUNEL-
positive nuclei, active caspase 3 immuno-positive myoﬁbres
and myoﬁbres with a cytosolic distribution of cytochrome c
(15). TUNEL-positive myocyte nuclei were also seen in an
alternative transgenic mouse model of OPMD in which a
PABPN1 transgene is expressed highly in all tissues under the
control of the CAG (cytomegalovirus enhancer and chicken
b-actin) promoter (13). Doxycycline (12), trehalose (16) and
cystamine (15) alleviate muscle weakness in A17 mice. These
drugs decrease A17 toxicity not only by reducing the aggrega-
tion of A17, but also appear to have distinct anti-apoptotic
effects. Additional evidence suggesting a role for apoptosis in
OPMD comes from cell and Drosophila models. Pathology in
aDrosophilamodelofOPMDcanbeamelioratedbyexpression
of the viral anti-apoptotic protein p35 (14). In addition, apopto-
tic markers are elevated in COS-7 and C2C12 cells transiently
expressing mutant PABPN1, and toxicity is reduced by
expression of the viral BCL2 homolog E1B19K (12).
Despite the presence of increased apoptosis in OPMD
models, it is unclear whether apoptosis is an important contri-
butor to the myoﬁbre loss and muscle weakness in this disease.
The role of apoptosis in muscle degeneration is not fully
understood. While apoptosis is thought to have a central role
in the pathology of some muscular dystrophies (17–27), its
role in others is unclear (17,28). It is also unclear how multi-
nucleated cells such as myoﬁbres co-ordinate cell death
signals and die. To directly assess the contribution of apopto-
sis to OPMD and test the relevance of apoptosis in vivo,w e
have crossbred A17 mice with mice that over-express BCL2
(B-cell CLL/lymphoma 2). BCL2 was initially identiﬁed as a
gene that is deregulated in follicular B-cell lymphomas due
to t(14;18) chromosomal translocations (29), and belongs to
a large family of pro- and anti-apoptotic proteins. The
balance and interactions between different BCL2-family pro-
teins control the mitochondrial apoptotic pathway and deter-
mines whether a cell lives or dies. Pro-apoptotic BAX
(BCL2-associated X protein) and BAK (BCL2 homologous
antagonist/killer) induce cell death by increasing the per-
meability of the mitochondrial membrane, causing the
release of cytochrome c, which leads to the activation of
downstream caspases (30). BCL2 antagonizes BAX/BAK acti-
vation and mice over-expressing BCL2 have decreased apop-
tosis (17). Here we demonstrate that BCL2 not only modiﬁes
the phenotype of OPMD model mice, but also regulates a
central pathway of myoﬁbre death in OPMD. BCL2 expression
reduces levels of apoptosis and markedly improves the
strength of A17 muscle at early time points.
RESULTS
BCL2 expression rescues muscle weakness in A17 mice
To genetically test the role of apoptosis in the pathogenesis of
OPMD, we introduced a BCL2 transgene into A17 mice. Mice
heterozgous for the A17 transgene [A17-1 mice (12)] were
crossed with mice heterozygous for a muscle-expressing
BCL2 transgene (17). These MRF4-hBCL2 mice express a
human BCL2 transgene at high levels in skeletal muscle under
control of the myogenin regulatory 4 promoter (17). All exper-
iments were carried out on F1 mice derived from crossing A17
mice on an FvB background with MRF4-hBCL2 mice on a
C57BL/6 background. Litters comprised F1 mice expressing
either A17 or BCL2 alone, non-transgenic mice and mice
expressing both A17 and BCL2 transgenes (A17 × BCL2
mice) (Fig. 1A). All mice were tested monthly up to the age
of 10 months. This allowed the observation of the effects of
BCL2 over-expression on early-stage muscle weakness and
late-stage locomotor defects that are part of the progressive,
mild, dystrophic phenotype of A17 mice.
All mice appeared normal at birth and there was no differ-
ence in grip strength of the forelimbs or all limbs between
non-transgenic, A17, BCL2 or A17 × BCL2 mice at 6
weeks of age (Fig. 1B and C). However, at 4 months of age,
A17 mice were weaker than non-transgenic littermates as
shown by grip strength of the forelimbs (Fig. 1B) and all
limbs (Fig. 1C). A17 develop a progressive muscle weakness
and had reduced grip strength compared with non-transgenic
mice at 4 months of age, grip strength steadily declined until
the end of the study (10 months of age). Muscle weakness
was not seen in mice expressing both A17 and BCL2 trans-
genes (A17 × BCL2 mice) at 4 months of age. BCL2
co-expression markedly improved grip strength in A17 mice,
and A17 × BCL2 mice had a signiﬁcantly increased forelimb
and all-limb grip strength compared with A17 mice from 4 to
8 months of age (Fig. 1B and C). The beneﬁcial effect of
BCL2 co-expression on the grip strength of A17 mice was
transient. A17 × BCL2 mice show a rapid decline in forelimb
muscle strength from  6 months of age and all-limb muscle
strength from  7 months of age and at 9 and 10 months of
age, A17 × BCL2 had a similar forelimb grip strength and
all-limb grip strength compared with A17 mice (Fig. 1B and
C). The muscle weakness in A17 × BCL2 mice from  9
months of age is not due to the loss of expression of the
BCL2 transgene; both A17 and BCL2 transgenes are robustly
expressed at 6 months and 11 months of age (Fig. 1A). The
expression of BCL2 alone had no effect on grip strength in
non-A17 mice, since BCL2 mice had a similar forelimb grip
strength and all-limb grip strength to non-transgenic mice at
all time points studied (Fig. 1B and C).
BCL2 co-expression also markedly improved the perform-
ance of A17 mice in accessory muscle strength tests (wire
manoeuvre, vertical gripping, pelvic elevation) at early time
points (Supplementary Material, Fig. S1). In many of these
tests, A17 × BCL2 mice had a similar performance to non-
transgenic mice at early time points. A17 × BCL2 mice per-
formed signiﬁcantly better than A17 mice at the wire
manoeuvre task from 4 to 8 months of age and there was no
signiﬁcant difference in the performance of non-transgenic
and A17 × BCL2 mice (Fig. 2A and Supplementary Material,
Fig. S1). However, muscle weakness became apparent in
A17 × BCL2 mice at later stages and there was no difference
in performance at the wire manoeuvre task of A17 and A17 ×
BCL2 mice at 9 and 10 months of age. Fewer A17 × BCL2
mice dragged their pelvis when walking, compared with
A17 mice at 8 and 9 months of age, but there was no signiﬁ-
cant difference in pelvic elevation between A17 and A17 ×
BCL2 mice at 10 months of age (Fig. 2B). A17 × BCL2
mice also had improved performance at the vertical gripping
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grip the vertical grid (rather than fall due to reduced muscle
strength), compared with A17 mice at 7 and 8 months of
age (Fig. 2C). However, there was no difference in perform-
ance at the vertical gripping task between A17 and A17 ×
BCL2 mice at 9 and 10 months of age (Fig. 2C). The
expression of BCL2 alone had no effect on performance at
any of these tasks and BCL2 mice performed the same as non-
transgenic mice at all time points studied (Supplementary
Material, Fig. S1). All groups performed similarly at 6
weeks of age (Fig. 2 and Supplementary Material, Fig. S1).
A17 mice have reduced weight compared with
non-transgenic littermates and the mean weight of A17
mice is increased by the co-expression of BCL2
We observed that A17 mice had a reduced body weight com-
pared with non-transgenic mice from the ages of 4–10 months
(Fig. 3A). A17 × BCL2 mice had a signiﬁcantly different dis-
tribution of body weights compared with A17 mice and had a
higher average body weight than A17 mice from 4 to 10
months of age (Fig. 3A). The expression of BCL2 alone did
not alter body weight, and BCL2 mice had similar body
weights to non-transgenic mice at all time points studied.
All groups had a similar weight distribution at 6 weeks of
age (Fig. 3A).
Given the differences in body weight between non trans-
genic, A17 and A17 × BCL2 mice, we were interested in
muscle mass of these mice. A17 mice had a reduced mass
of the tibialis anterior (TA) and quadriceps muscle compared
with non-transgenic mice at 6 months of age (Fig. 3B) and 11
months of age (Fig. 3C). The mass of the TA and quadriceps
muscles was increased in A17 × BCL2 mice compared with
A17 mice at 6 months of age (Fig. 3B) and at 11 months of
age (Fig. 3C).
Figure 1. BCL2 expression improves grip strength at early time points in a mouse model of OPMD. (A) Western blot of biceps muscle lysates from 6 months and
11 months, A17 mice, non-transgenic mice (NT), BCL2 mice and A17 × BCL2 mice probed with antibodies against PABPN1 or human BCL2 (to show trans-
gene levels). Tubulin was used as a loading control. (B and C) Forelimb grip strength (B) and grip strength of all limbs (C) of male A17 mice (black triangle; 6
weeks, n ¼ 17; 4, 5 and 6 months, n ¼ 17; 7 and 8 months, n ¼ 13, 9 and 10 months, n ¼ 12), non-transgenic mice (NT; grey diamond; 6 weeks, n ¼ 14; 4, 5 and
6 months, n ¼ 14; 7 and 8 months, n ¼ 11; 9 and 10 months, n ¼ 10), BCL2 mice (black square; 6 weeks, n ¼ 17; 4, 5 and 6 months, n ¼ 17; 7 and 8 months,
n ¼ 13; 9 and 10 months, n ¼ 12) and mice expressing both A17 and BCL2 transgenes (A17 × BCL2; open circle; 6 weeks, n ¼ 17; 4, 5 and 6 months, n ¼ 17;
7, 8, 9 and 10 months, n ¼ 14). (B) Forelimb grip strength was improved in A17 × BCL2 mice compared with A17 mice at 4 months (P , 0.0001), 5 months
(P , 0.0001), 6 months (P , 0.0001), 7 months (P , 0.0001) and 8 months (P ¼ 0.0003) of age but not at 9 months (P ¼ 0.08) and 10 months (P ¼ 0.06) of
age. Repeated measure ANOVAs for determination of the overall effect from all time points P, ,0.0001. (C) Grip strength from all limbs was improved in
A17 × BCL2 mice compared with A17 mice at 4 months (P , 0.0001), 5 months (P , 0.0001), 6 months (P , 0.0001), 7 months (P , 0.0001) and 8
months (P ¼ 0.0006) of age but not at 9 months (P ¼ 0.06) and 10 months (P ¼ 0.3) of age. Repeated measure ANOVAs for determination of the overall
effect from all time points P, ,0.0001. No signiﬁcant difference in forelimb grip strength or grip strength from all limbs was seen between BCL2 mice and
non-transgenic mice at all time points studied, or between any of the different groups at 6 weeks of age. Data were analysed using two-tailed Student’s
t-tests at each individual time point. Error bars represent SD.
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mice, even at late stages when BCL2 fails to rescue muscle
weakness
We hypothesized that BCL2 co-expression would rescue
muscle weakness by reducing levels of apoptosis in A17
mice. We were also interested to test levels of apoptosis at
later stages in A17 mice, when BCL2 co- expression does
not protect against muscle weakness. In accordance with pre-
vious data (12), we observed an increase in the number of
TUNEL-positive nuclei in biceps muscle sections from A17
mice compared with non-transgenic mice at both 6 and 11
months of age (Fig. 4A). The number of TUNEL-positive
nuclei was reduced in A17 × BCL2 mice compared with
A17 mice at both 6 and 11 months of age (Fig. 4A). A17 ×
BCL2 mice have similar levels of TUNEL-positive nuclei to
non-transgenic mice, even at 11 months of age when A17 ×
BCL2 mice manifest muscle weakness. Interestingly, the
number of myoﬁbre nuclei containing PABPN1-labelled
aggregates was increased in muscle sections from A17 ×
BCL2 mice, compared with A17 mice at both 6 and 11
months of age (Fig. 4B and C). This phenomenon may be
due to increased survival times of aggregate-containing myo-
ﬁbres due to BCL2.
Muscle sections from A17 mice showed an increase in the
number of muscle ﬁbres with a diffuse localization of cyto-
chrome c (as opposed to mitochondrial localization, corre-
sponding to cytochrome c release from the mitochondria)
(Fig. 5A) and an increased number of muscle ﬁbres positive
for active caspase 3 (Fig. 5B) compared with sections from
non-transgenic mice. These apoptotic markers were reduced
in biceps muscle sections from A17 × BCL2 mice compared
with A17 mice (Fig. 5A and B). The number of muscle
ﬁbres with a diffuse localization of cytochrome c (Fig. 5A)
and number of muscle ﬁbres positive for active caspase 3
(Fig. 5B) were decreased to non-transgenic levels in A17 ×
BCL2 mice, even at 11 months of age, suggesting that the
muscle weakness seen at late stages in A17 × BCL2 mice is
not due to excess apoptosis.
We also compared the histology of muscle sections from
A17 and A17 × BCL2 mice and observed a decrease in the
number of centralized nuclei (as a percentage of the total myo-
blast nuclei scored) in haematoxylin and eosin stained biceps
sections from 6-month old A17 × BCL2 mice compared with
Figure 2. BCL2 expression transiently improves muscle strength in a mouse model of OPMD. Male A17 mice (black bar; 6 weeks, n ¼ 17; 4, 5 and 6 months,
n ¼ 17; 7 and 8 months, n ¼ 13; 9 and 10 months, n ¼ 12) and male A17 × BCL2 mice (open bar; 6 weeks, n ¼ 17; 4, 5 and 6 months, n ¼ 17; 7, 8, 9 and 10
months, n ¼ 14) were compared in strength tests. (A) A17 × BCL2 mice performed better than A17 mice at the wire manoeuvre task at 4, 5, 6, 7 and 8 months of
age but not at 9 and 10 months of age. Score: 0, active grip with hind legs; 1, difﬁculty grasping with hind legs; 2, unable to lift hind legs; 3, falls within3 0s ;4 ,
falls immediately. (B) Pelvic elevation was improved in A17 × BCL2 mice compared with A17 mice at the ages of 7 and 8 months but not at 9 and 10 months.
Score: 2, normal elevation; 1, barely touches; 0, markedly ﬂattened. (C) A17 × BCL2 males performed signiﬁcantly better at the vertical gripping test at 8 and 9
months of age, but not at 10 months of age, compared with A17 males. Score: 0, grips the grid; 1, falls off the grid. ∗P , 0.05; ∗∗P , 0.001; ∗∗∗P , 0.0001; NS,
non-signiﬁcant. Non-parametric data from the wire manoeuvre and pelvic elevation tests were analysed using Mann–Whitney U-tests and we used Chi-squared
tests to analyse vertical gripping data.
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no difference in the percentage of centralized nuclei in muscle
sections from A17 × BCL2 mice compared with A17 mice.
After regeneration, muscle ﬁbres are centrally nucleated. Cen-
tralized nuclei are thought to represent the degenerative/regen-
erative process occurring in muscle and are routinely used as a
marker of dystrophic injury and subsequent regeneration
(31,32).
DISCUSSION
Here we provide evidence that apoptosis is a major contribu-
tor to muscle weakness that is a characteristic feature of
OPMD. Genetically blocking apoptosis by the over-
expression of BCL2 ameliorates muscle weakness in A17
mice. Between 4 and 8 months of age, A17 × BCL2 mice
perform better than A17 mice at grip strength, wire
manoeuvre and vertical gripping tasks, and this is associated
with a reduction in apoptotic markers in muscle sections. The
co-expression of BCL2 in A17 mice has a large rescue effect
on muscle weakness, with A17 × BCL2 mice performing
similar to non-transgenic mice in many strength tests. This
suggests an important role for excessive apoptosis in the
pathogenesis of OPMD in vivo, at least early in the disease
process.
We observed that A17 mice have reduced body weights
compared with non-transgenic mice. This difference has
not been so apparent in our previous studies when the A17
Figure 3. Weight differences between non-transgenic, A17, BCL2 and A17 × BCL2 mice. (A) Body weight of male A17 mice (black triangle; 6 weeks, n ¼ 17;
4, 5 and 6 months, n ¼ 17; 7 and 8 months, n ¼ 13, 9 and 10 months, n ¼ 12), non-transgenic mice (NT; grey diamond; 6 weeks, n ¼ 14; 4, 5 and 6 months, n ¼
14; 7 and 8 months, n ¼ 11; 9 and 10 months, n ¼ 10), BCL2 mice (black square; 6 weeks, n ¼ 17; 4, 5 and 6 months, n ¼ 17; 7 and 8 months, n ¼ 13; 9 and 10
months, n ¼ 12) and mice expressing both A17 and BCL2 transgenes (A17 × BCL2; open circle; 6 weeks, n ¼ 17; 4, 5 and 6 months, n ¼ 17; 7, 8, 9 and 10
months, n ¼ 14). Male A17 mice on a mixed FvB C57BL/6 background weighed less than non-transgenic littermates at 4 months (P ¼ 0.0001), 5 months (P ,
0.0001), 6 months (P ¼ 0.0004), 7 months (P ¼ 0.004), 8 months (P ¼ 0.0008), 9 months (P ¼ 0.002) and 10 months of age (P ¼ 0.002). Repeated measure
ANOVAs for determination of the overall effect from all time points P, ,0.0001. Co-expression of BCL2 in A17 mice alters the distribution of body
weights, and A17 × BCL2 mice generally weighed more than A17 mice at 4 months (P ¼ 0.04), 5 months (P ¼ 0.02), 6 months (PP ¼ 0.04), 7 months
(P ¼ 0.009), 8 months (P ¼ 0.03), 9 months (P ¼ 0.03) and 10 months of age (P ¼ 0.008) (repeated measure ANOVAs for determination of the overall
effect from all time points P, ,0.0001). The expression of BCL2 alone does not alter body weight, and there was no signiﬁcant difference in body weight
between BCL2 mice and NT mice at any time point studied. There was no difference in body weight between any of the groups at 6 weeks of age.
(B) Muscle mass of quadriceps and tibilias anterior muscles from 6-month-old A17, NT, BCL2 and A17 × BCL2 mice (n ¼ 3). (C) Muscle mass of quadriceps
and tibilias anterior muscles from 11-month-old A17, NT, BCL2 and A17 × BCL2 mice (n ¼ 3). ∗P , 0.05; ∗∗P , 0.001; ∗∗∗P , 0.0001; NS, non-signiﬁcant.
Error bars represent SEM.
1158 Human Molecular Genetics, 2011, Vol. 20, No. 6transgene was on the FvB background (12,15). The larger
difference in body weight between A17 and non-transgenic
mice seen in this study may be due to the A17
transgene being expressed on a mixed FvB C57BL/6 back-
ground. A17 × BCL2 mice have a higher average body
weight than A17 mice. We also show differences in muscle
mass. TA and quadriceps muscle mass are reduced in A17
mice compared with non-transgenic mice. This reduction in
muscle mass is likely to be due to muscle atrophy that has
been demonstrated in A17 mice (33). Co-expression of
BCL2 in A17 mice reduces atrophy and the mass of TA and
quadriceps muscles is increased in A17 × BCL2
mice compared with A17 mice. Interestingly, a recent study
has suggested that muscle wasting and atrophy in
myotonic dystrophy primarily results from activation of apop-
tosis (34).
The dramatic improvement in muscle strength of A17 mice
due to BCL2 co-expression is transient, and BCL2 over-
expression afforded protection against muscle weakness at 8,
9 and 10 months of age. This muscle weakness occurred
despite a marked reduction in apoptotic markers like TUNEL-
positive nuclei, myoﬁbres labelled for active-caspase 3 and
myoﬁbres showing a diffuse localization of cytochrome c, in
the A17 × BCL2 mice at 11 months of age. Indeed, at 11
months of age, muscle sections from A17 × BCL2 mice had
levels of apoptotic markers similar to non-transgenic mice.
This suggests that other cell death pathways may be activated
in A17 × BCL2 mice from  8 months of age, or that the A17
insult eventually causes muscle weakness via mechanisms dis-
tinctfromcelldeath.Whileapoptosisisunlikelytobetheexclu-
sivepathwayofmyoﬁbredeathinA17muscle,ourdata suggest
that apoptosis is the major pathway.
Figure 4. Cell death and aggregate load in A17 mice and mice expressing both A17 and BCL2 transgenes. (A) Biceps muscle sections from 6-month-old and
11-month-old A17 (black bar), NT (grey bar) and A17 × BCL2 (open bar) mice were TUNEL labelled and the number of positive nuclei scored. (B) Repre-
sentative images of PABPN1-labelled aggregates (green) in biceps muscle sections from 6-month-old A17 mice and A17 × BCL2 mice. Sections were
treated with KCl prior to labelling to remove soluble proteins (aggregates are resistant) and hence no signal is seen in sections from non-transgenic (NT)
mice. Nuclei were visualized using DAPI (blue). (C) Quantiﬁcation of the number of nuclei containing PABPN1-labelled aggregates in sections from
6-month-old and 11-month-old A17 mice (black bar) and A17 × BCL2 (open bar) mice treated as (B). n ¼ 3; ∗P , 0.05; ∗∗∗P , 0.0001. Error bars represent
SEM.
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OPMD and it may be involved in the pathogenesis of other
muscular dystrophies. Apoptotic markers have been observed
in biopsy samples from some muscular dystrophy patients (35)
and in mouse models of muscular dystrophy (27,36). Apopto-
sis and the activation of apoptotic pathways are evident in
mouse models of myopathy including collagen VI-deﬁcient
mice (22), caveolin-3 mutant mice that model limb girdle mus-
cular dystrophy (24) and calpain 3-deﬁcient mice that model
limb girdle muscular dystrophy type 2A (20). Anti-apoptotic
strategies, such as blocking the mitochondrial permeability
transition pore by treatment with cyclosporine A, have been
shown to rescue mouse models of collagen VI deﬁciency
(22) and correct mitochondrial dysfunction and muscle apop-
tosis in patients with collagen VI myopathies (19). In addition,
blocking apoptosis by the over-expression of BCL2 amelio-
rates muscle disease in a laminin a-2-deﬁcient mouse model
of congenital muscular dystrophy (17,18). However, BCL2
over-expression failed to attenuate the disease phenotype of
the mdx mouse (18). Thus, in Duchenne and certain other
muscular dystrophies, it is possible that other cell death
pathways such as necrosis may be more important mediators
of pathology, and death of myoﬁbres may result from the
interplay of various pathways.
While we propose that apoptosis is central to OPMD, the
therapeutic value of blocking apoptosis using BCL2 induction
in muscle may be limited by its tractability. However, the
BCL2 experiment provides further mechanistic support for
the consideration of drugs such as doxycycline, trehalose
and cystamine which attenuate the disease phenotype of our
mouse model of OPMD. Doxycycline (12), trehalose (16)
and cystamine (15) act, in part, by inhibiting apoptosis but
also have effects upstream of the induction of apoptosis such
as reducing the aggregation of mutant PABPN1 (doxycycline,
trehalose and cystamine), decreasing transglutaminase 2
activity (cystamine) and reducing levels of mutant PABPN1
(trehalose). Doxycycline has also been used to alleviate the
disease phenotype of the laminin a-2-deﬁcient mouse and
this is thought to occur via its inhibitory action on apoptosis
(37). While the almost complete block of apoptosis by the
Figure 6. A central role for apoptosis in the pathogenesis of OPMD. The
expression of mutant PABPN1 (A17) results in increased levels of BAX
(12). This causes the activation of the apoptotic cascade (12,15). Cytochrome
c is released from the mitochondria to the cytosol where it can bind additional
factors to form the apoptosome complex. The apoptosome complex causes the
conversion of procaspases to their active, mature caspase form and ultimately
results in the activation of caspase 3, otherwise known as the executioner
caspase. Here we have provided data to further support a central role of apop-
tosis in the pathogenesis of OPMD. Genetically blocking apoptosis by the
over-expression of BCL2 ameliorates A17 toxicity. BCL2 most likely acts
to block A17 toxicity by binding the excess BAX and sequestering it away
from the mitochondria. Wild-type PABPN1 has an opposing effect on apopto-
sis and increases the translation of XIAP, a caspase inhibitor (38). It is likely
that OPMD is primarily caused by a toxic gain of function of mutant PABPN1
that results in the activation of apoptosis. However, the loss of the anti-
apoptotic function of wild-type PABPN1 may also contribute to pathology.
Figure 5. Apoptotic markers are elevated in muscle from A17 mice and
reduced by BCL2 co-expression. (A) Quantiﬁcation of the number of myoﬁ-
bres with a diffuse pattern of cytochrome c labelling (corresponding to cyto-
chrome c release from the mitochondria to cytosol and indicating apoptotic
myoﬁbres) in biceps muscle sections from 6-month-old and 12-month-old
NT, A17 and A17 × BCL2 mice. (B) Biceps muscle sections from
6-month-old and 12-month-old NT, A17 and A17 × BCL2 mice were labelled
with an active caspase 3 antibody and the number of immuno-positive myoﬁ-
bres were scored. (C) Quantiﬁcation of the number of centralized nuclei in
H&E stained biceps sections from 6-month-old and 12-month-old NT, A17
and A17 × BCL2 mice. Apoptotic markers are reduced in A17 × BCL2
mice to NT levels even at 11 months when BCL2 does not rescue phenotype
and muscle weakness is apparent in A17 × BCL2 mice (n ¼ 3). ∗∗P , 0.001;
∗∗∗P , 0.0001; NS, non-signiﬁcant. Error bars represent SEM.
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muscle weakness and pathology in the OPMD mouse at
early time points, the BCL2 overexpression was not beneﬁcial
at later time points. It is likely that when apoptosis is blocked,
there is an activation of alternative cell death pathways that
cause the termination of a dysfunctional muscle ﬁbre that is
already committed to die. Apoptosis is central to OPMD but
is a downstream event in pathology. It may be more beneﬁcial
to additionally target events that are upstream of apoptosis in
OPMD pathogenesis, such as the aggregation of mutant
PABPN1 and the levels (degradation) of mutant PABPN1.
Theoretically, the long-term upregulation of BCL2 and the
subsequent blocking of apoptosis could have adverse effects
in the mouse such as tumourogenesis. However, mice over-
expressing BCL2 speciﬁcally in muscle (MRF4-hBCL2
mice) do not develop a phenotype (17,18) and in this study
were indistinguishable from non-transgenic mice up to 11
months of age (when sacriﬁced in this study).
We now propose a model where apoptosis is central to
OPMD (Fig. 6). We have previously shown that the expression
of mutant PABPN1 (A17) results in increased levels of BAX
and the upregulation of apoptotic markers (12,15). While the
expression of mutant PABPN1 induces cell death, wild-type
PABPN1 is protective and can reduce toxicity caused by
pro-apoptotic agents and mutant PABPN1 expression via the
translational regulation of X-linked inhibitor of apoptosis
(XIAP) (38). It is possible that there is a loss-of-function
element to OPMD, as the increase in protein levels of XIAP
in skeletal muscle of A10 mice was not seen in muscle from
A17 mice (38). Here we have shown that genetically blocking
apoptosis by the over-expression of BCL2 ameliorates A17
toxicity. BCL2 most likely acts to block A17 toxicity by
binding the excess BAX and sequestering it away from the
mitochondria. We have previously used apoptosis as a
marker for the toxicity of mutant PABPN1 in our cell and
mouse models of OPMD. However, it is likely that the apop-
totic pathway is major contributor to muscle weakness and
dysfunction in OPMD.
MATERIALS AND METHODS
Transgenic mice
AllstudiesandprocedureswerecarriedoutfollowingUKHome
Ofﬁce regulations and animals were caged under standard con-
ditions (12 h light, 12 h dark; food and water available ad
libitum). OPMD transgenic mice [A17-1 mice (12)] express a
mutant, expanded PABPN1 transgene under control of the
human skeletal actin (HSA) promoter on the FvB background
(12). Mice expressing human BCL2 under control of the myo-
genin regulatory factor 4 (MRF4) promoter (MRF4-hBCL2
mice) were obtained from J Boone Miller and J Dominov,
Boston Biomedical Research Institute, and are on the C57BL/
6 background (17). Mice heterozygous for the A17 transgene
were crossed with mice heterozygous for the human BCL2
transgene to produce F1 litters comprising non-transgenic
mice, mice expressing the A17 transgene (A17 mice), mice
expressing thehBCL2transgene(BCL2 mice)andmiceexpres-
singboththeA17andhBCL2transgene(A17 × BCL2mice)on
a mixed F1 FvB C57BL/6 background.
Genotyping
Genotype was determined using PCR. Genomic DNA was iso-
lated from ear biopsies by lysis in 0.25 mg/ml proteinase K in
1% SDS, 100 mM NaCl, 100 mM EDTA, 50 mM Tris, pH 8 at
558C for 1 h inthe presence of 10% (w/v) chelex (Bio Rad Lab-
oratories). Proteinase K was inactivated by incubating the
sampleat958Cfor15 min.Chelexwasprecipitatedbycentrifu-
gation and the supernatant, containing genomic DNA, was used
forPCR.WedeterminedthepresenceofthePABPN1transgene
using the primers 5′-GAACCAACAGACCAGGCATC-3′ and
5′-AGGACTGACACGTGCTACGA-3′. The hBCL2 transgene
was detected using the primers 5′-TAGATGTTCTGGGG
AGCACTAGC-3′ and 5′-CACTCGTAGCCCCTCTGCGA
CAG-3′. The PCR mix contained  20–100 ng genomic
DNA, 200 mM dNTPs, 100 nM each primer, 2 units Taq DNA
polymerase I (5 units/ml; Promega) in 1 × buffer (50 mM KCl,
10 mM Tris-Cl, pH 9.0, 0.1% Triton
w X-100; Promega) sup-
plemented with 1.5 mM MgCl2 and 5% DMSO. Fragments
were ampliﬁed under the following PCR conditions: 948C for
1 min; 608C for 2 min, 728C for 1 min for 30 cycles; then
728C for 10 min.
Strength testing of mice
F1, male non-transgenic, A17, BCL2 and A17 × BCL2 mice
were tested at 6 weeks of age, then monthly from 4 months
of age. Mice were given alphanumeric identities that provided
no clue to genotype. Grip strength of the forelimbs and all
limbs was assessed using a grip strength metre (Bioseb).
Wire manoeuvre, pelvic elevation and vertical gripping are
part of the SHIRPA battery of behavioural tests (39). For the
wire manoeuvre, we held mice above a horizontal wire by
the tail and lowered them to allow the forelimbs to grip the
wire. Mice were held in extension, rotated around to the hori-
zontal and released. Mice were scored as follows: 0, active
grip with hind legs; 1, difﬁculty grasping with hind legs; 2,
unable to lift hind legs; 3, falls within 30 s; 4, falls immedi-
ately. For the vertical gripping test, we placed mice on a hori-
zontal grid that was gripped with both forelimbs and hind
limbs. We raised the grid to the vertical and scored mice as
follows: 0, grips the grid; 1, falls off the grid. We also assessed
mice for elevation of the pelvis when walking and scored them
as follows: 0, markedly ﬂattened; 1, barely touches; 2, normal
(3 mm elevation). We analysed non-parametric data from the
wire manoeuvre and pelvic elevation tests at each time point
using Mann–Whitney U-tests (STATVIEW software,
version 4.53; Abacus Concepts). We used Chi-squared tests
to analyse vertical gripping data. We analysed grip strength
meter data from each treatment time point with unpaired
t-tests and the overall effect from all treatment time points
with repeated-measures ANOVA (STATVIEW software,
version 4.53; Abacus Concepts).
Western blotting
Lysates were prepared by homogenizing tissue in 50 mM
Tris–HCl pH 7.4, 0.5% Triton X-100 with protease inhibitor
cocktail (Complete; Roche Diagnostics). Proteins were separ-
ated on 10% SDS–polyacrylamide gels and transferred onto
Human Molecular Genetics, 2011, Vol. 20, No. 6 1161nitrocellulose membranes (Hybond ECL membrane;
Amersham Biosciences), which were blocked by incubation
in 5% dried milk in 0.1 M PBS, 0.1% Tween-20, pH 7.6. Mem-
branes were probed with primary antibodies raised against
PABPN1 (1:10,000), human BCL2 (Cell Signalling Technol-
ogies; 1:1000) or as loading control tubulin (Sigma Aldrich;
1:1000). HRP-conjugated antibodies (Amersham Biosciences;
1:5000) were then added to the blots. Immuno-reactive bands
were detected with enhanced chemiluminescence reagent
(ECL; Amersham Biosciences) and signal visualized by the
exposing membrane to ECL Hyperﬁlm (Amersham Bio-
sciences).
Histology
Tissue was snap frozen in liquid nitrogen-cooled isopentane
and 10 mm sections were cut on a cryostat (Leica Microsys-
tems) to poly-L-lysine-coated slides. Sections were ﬁxed in
acetone. For immuno-labelling, slides were blocked with 1%
normal goat serum in 0.1 M PBS, 0.1% Triton X-100 and
then incubated, at 48C overnight, in primary antibody
diluted in 1% normal goat serum in 0.1 M PBS, 0.1% Triton
X-100. Primary antibodies used were anti-PABPN1
(1:1000), cytochrome c (Pharmingen; 1:500) or active
caspase 3 (Promega; 1:250). Slides were washed in 0.1 M
PBS, 0.1% Triton X-100 and incubated in ﬂuorophore-
conjugated secondary antibody (Alexa Fluor 488 goat anti-
rabbit or Alexa Fluor 594 goat anti-mouse; 1:1000; Molecular
Probes) for 2 h at room temperature in the dark. Slides were
washed again and sections mounted in citiﬂuor (Citiﬂuor
Ltd.) containing 4′,6-diamidino-2-phenylindole (DAPI; 3 mg/
ml; Sigma-Aldrich Ltd.) to visualize nuclei. To remove
soluble proteins, sections were incubated in 1 M KCl, 30 mM
HEPES, 65 mM PIPES, 10 mM EDTA, 2 mM MgCl2, pH 6.9
for 1 h at room temperature prior to immuno-labelling. Aggre-
gates are resistant to this KCl treatment. As negative controls
to check for non-speciﬁc ﬂuorescence, sections were pro-
cessed as above but with either primary or secondary antibody
omitted. For histological analysis of muscle morphology and
pathology, sections were stained with haemotoxylin and
eosin (H&E). Fluorescent DNA fragmentation (TUNEL; term-
inal deoxynucleotidyl transferase-mediated dUTP nick end
labelling) assay was carried out on skeletal muscle sections
using a standard kit (ApoAlert DNA fragmentation assay kit;
BD Biosciences).
Nuclei that contained aggregates, TUNEL-positive nuclei,
centralized nuclei, myoﬁbres immunoreactive for active
caspase 3 and myoﬁbres with a diffuse, cytosolic pattern of
cytochrome c labelling were scored. Three samples per
group and 200 nuclei per sample were scored with the
viewer blind to the identity of the slide. Pooled estimates
were calculated as odds ratios [OR; the ratios of the proportion
of aggregate containing/normal (or TUNEL positive/TUNEL
negative) nuclei in different experimental conditions] with
95% conﬁdence intervals, as described previously. OR and
P-values were determined by unconditional logistical
regression analysis using the general log linear analysis
option of SPSS Version 6.1. Images were taken with a
LSM510 confocal microscope (Leica).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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